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Edited by Thomas L. JamesAbstract Transportan is a chimeric cell-penetrating peptide
constructed from the peptides galanin and mastoparan, which
has the ability to internalize living cells carrying a hydrophilic
load. In this study, we have determined the NMR solution
structure and investigated the position of transportan in neutral
bicelles. The structure revealed a well-deﬁned -helix in the
C-terminal mastoparan part of the peptide and a weaker
tendency to form an -helix in the N-terminal domain. The
position of the peptide in relation to the membrane, as studied by
adding paramagnetic probes, shows that the peptide lies parallel
to, and in the head-group region of the membrane surface. This
result is supported by amide proton secondary chemical shifts.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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It has been discovered that several short peptides, so called
cell-penetrating peptides (CPPs), have the capability to trans-
fer large hydrophilic cargos into living cells without destroying
the cell. The prospect of using CPPs for delivery of drugs into
the cell puts them into focus of intensive research [1,2]. The
translocation through the membrane was originally thought
not to be dependent on active transport or receptors, but
several recent ﬁndings have shown that the translocation
mechanism may involve diﬀerent pathways for diﬀerent pep-
tides and cargoes, as well as in diﬀerent membrane environ-
ments. In recent studies it was shown that ﬂuorescence
microscopy on ﬁxed cells, which is a method by which several
translocation observations have been made, can give artifac-
tual uptake of peptide associated with the plasma membrane,
and that endocytotic pathways may dominate for many sys-
tems [3–5]. Other translocation mechanisms have also been* Corresponding author. Fax: +46-8-155597.
E-mail address: lena.maler@dbb.su.se (L. M€aler).
Abbreviations: NMR, nuclear magnetic resonance; CD, circular
dichroism; SDS, sodium dodecyl sulfate; CPP, cell-penetrating peptide;
DMPC, 1,2-dimyristoyl-sn-glycero-3-phosphocholine; DHPC, 1,2-di-
hexanoyl-sn-glycero-3-phosphocholine; TSPA, 3-trimethylsilyl-propi-
onic acid-d4; DPC, dodecyl phosphocholine; NOESY, nuclear
Overhauser eﬀect spectroscopy; NOEs, proton–proton distances
shorter than 6 A as determined from NOESY cross-peaks; TOCSY,
total correlation spectroscopy; RMSD, root mean square deviation
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doi:10.1016/j.febslet.2004.04.079proposed [6,7], and since the mechanism of cell internalization
is not fully known, further work is needed in order to clarify
whether the internalization is dependent on the structure of the
peptide or on the orientation of the peptide in relation to the
membrane.
Transportan is a 27 residues long peptide with the sequence:
GWTLNSAGYLLGKINLKALAALAKKIL-amide. It is a
chimeric peptide constructed from 12 amino acid residues de-
rived from the N-terminal part of the neuropeptide galanin
linked with a lysine residue to the 14 amino acids of the wasp
venom mastoparan. Transportan can, in contrast to the gala-
nin and mastoparan peptides alone, translocate through bio-
logical membranes and carry large hydrophilic cargos into the
cell without destroying the membrane [8,9].
In a 1H NMR (nuclear magnetic resonance) study of
transportan in aqueous solution with sodium dodecyl sulfate
(SDS) micelles, it was observed that the C-terminal mastopa-
ran part displays a-helical secondary chemical shifts, while the
galanin part is less structured. This is in agreement with what
has been observed for the two peptide fragments (mastoparan
and galanin) alone [10]. In order to further understand how the
structures of CPPs are related to the translocating ability, a
larger database of such structures is required. There are only a
few examples of solution structures of CPPs in membrane
mimetic solvents, mainly of penetratin, derived from the third
helix of the Antennapedia transcription factor [11]. Therefore,
we have determined the three-dimensional structure of trans-
portan in a membrane-like environment, composed of
phospholipid bicelles.
Bicelles are disk-shaped aggregates formed by mixing two
amphiphilic molecules with diﬀerent chain lengths. The size
of the bicelle is controlled by changing the ratio of long-
chained lipid to short-chained lipid (q). Small isotropic bi-
celles (with q < 0:5) are suitable for high-resolution NMR
studies of membrane interacting peptides [12]. 1,2-Dimyri-
stoyl-sn-glycero-3-phosphocholine (DMPC) is often used as
the long-chained lipid, while 1,2-dihexanoyl-sn-glycero-3-
phosphocholine (DHPC) is employed as the short-chained
lipid. These zwitterionic phospholipids form stable bicelles
over a relatively wide range of temperatures, concentrations,
pH, and phospholipid compositions [13,14]. Phospholipid
bicelles have many advantages as a membrane mimetic
compared to micelles, which are commonly used in NMR
investigations of membrane interacting molecules. Some
enzymes (e.g., diacylglycerol kinase) that lose their biologi-
cal activity in a micelle environment have been shown to
maintain their function in bicelles [15]. For studies ofblished by Elsevier B.V. All rights reserved.
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they resemble the surface of a membrane better than micelles
[14,16]. The position of a peptide in a micelle can diﬀer sig-
niﬁcantly from the position in a phospholipid bilayer [10,17].
Positioning studies in bicelles are therefore preferred over
corresponding studies in micelles.-40
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Fig. 1. CD-spectra for 1 mM transportan in DPC micelles in 50 mM
phosphate buﬀer (a); for 1 mM transportan in neutral bicelles
([DMPC]/[DHPC]¼ 0.33) with 50 mM phosphate buﬀer, pH 5.6 (b);
and for 3 mM transportan in pure H2O (c). The temperature was 37 C.2. Materials and methods
2.1. Sample preparation
Transportan was obtained from Neosystem Labs and used as re-
ceived. DMPC and DMPC-d54, and DHPC and DHPC-d22, as well as
the spin-labelled lipids, 1-palmitoyl-2-steroyl-(5-DOXYL)-sn-glycero-
3-phosphocholine and 1-palmitoyl-2-steroyl-(12-DOXYL)-sn-glycero-
3-phosphocholine, were purchased from Avanti Polar Lipids. Samples
were produced by mixing peptide and DMPC powder in phosphate
buﬀer (50 mM, pH 5.6). A 1 M solution of DHPC-d22 was added to
produce a sample with 1 mM peptide concentration, 300 mM total
lipid and q¼ [DMPC]/[DHPC]¼ 0.33. For NMR samples, DMPC-d54
and DHPC-d22 were used. 10% D2O was added for ﬁeld/frequency
lock stabilization and 0.1 mM of 3-trimethylsilyl-propionic acid-d4
(TSPA) was added as an internal reference. The sample containing
transportan in dodecyl phosphocholine (DPC) was obtained by dis-
solving transportan in 300 mM aqueous DPC solution to yield a 1 mM
peptide concentration.
2.2. Circular dichroism spectroscopy
Circular dichroism (CD) measurements were recorded for trans-
portan in q ¼ 0:33 zwitterionic bicelles and in DPC micelles, as well as
in pure water. Spectra were collected on a Jasco J-720 CD spectro-
polarimeter using a 0.05 mm quartz cuvette. Wavelengths ranging
from 190 to 250 nm were measured, with a 0.2 nm step resolution and
100 nm/min speed. The temperature was controlled by a PTC-343
controller and set to 37 C. Spectra were collected and averaged over
16 scans. The a-helical content was estimated from the mean residue
molar ellipticity at 222 nm, assuming a two-state equilibrium between
a-helix and random coil conformation, Ha-helix ¼ 35700  cm2/dmol,
and HRC ¼ 3900  cm2/dmol [18].
2.3. NMR spectroscopy
NMR spectra were recorded on a Varian Inova spectrometer oper-
ating at a 1H frequency of 800 MHz at 37 C. Two-dimensional nu-
clear Overhauser eﬀect spectroscopy (NOESY) [19] and total
correlation spectroscopy (TOCSY) [20] spectra were typically collected
as 2048 512 data point matrices using 32–64 scans. NOESY spectra
were collected using two diﬀerent mixing-times, 70 and 100 ms.
TOCSY spectra were collected with mixing-times of 30 and 60 ms.
Water-suppression was achieved with the WATERGATE method [21].
Data processing was done with FELIX (Accelrys, version 2000.1) and
included zero-ﬁlling to 4096 2048 points and multiplication with a
shifted sine-bell function prior to Fourier transform.
2.4. Structure calculation
551 cross-peaks in the NOESY spectrum (smix ¼ 100 ms) recorded at
800 MHz were integrated, and the peak intensities were divided into
four groups, which were given the upper distance limits 3.0, 3.5, 4.5
and 6.0 A. This was done by normalizing the intensities against known
distances as described previously [22]. In all, 220 upper distance con-
straints were unambiguously determined in this way and then used to
calculate the structure. Structures were generated using DYANA,
version 1.5, using standard annealing algorithms [23]. A total of 60
structures were calculated and a ﬁnal ensemble of 25 structures was
selected, based on the DYANA target function, to represent the ﬁnal
solution structure. No structures within the ﬁnal ensemble had any
distance violations larger than 0.15 A. Analyses of the structures, in-
cluding analyses of secondary structure, were performed with the
PROCHECK NMR software [24] and visual analyses were performed
with Insight (Accelrys, version 2000.1). Root mean square deviations
(RMSDs) were calculated and overlays of structures were done with
the program Suppose (http://www.scripps.edu/~jsmith/suppose). The
coordinates of the ﬁnal ensemble of structures together with the NMR-derived input constraints have been deposited with the Protein Data
Bank (www.rcsb.org) under accession code 1SMZ.
2.5. Positioning studies
1-Palmitoyl-2-steroyl-(5-DOXYL)-sn-glycero-3-phosphocholine and
1-palmitoyl-2-steroyl-(12-DOXYL)-sn-glycero-3-phosphocholine were
dissolved in methanol-d4 to yield a concentration of 100 mM lipid.
Spin-labelled lipids were added to the sample of transportan in bicelles
to yield a concentration of 0.5 mM doxyl-labelled lipid. The eﬀect of
the spin-labels on peak heights in a 2D TOCSY spectrum (smix ¼ 30
ms) was monitored by recording a TOCSY spectrum prior to adding
the spin-labelled lipid and after addition of spin-labelled lipid. The
eﬀect of adding the doxyl-labelled lipids was evaluated from changes in
amplitudes of the HN–Ha cross-peaks relative to spectra without the
paramagnetic probe.3. Results
3.1. CD spectroscopy of transportan
CD spectroscopy was used to investigate the overall con-
formation of transportan in DPC micelles, zwitterionic bicelles
and H2O (Fig. 1). The measured mean molar ellipticities at 222
nm are )11 120  cm2/dmol in bicellar solution, )16 230  cm2/
dmol in DPC and )5860  cm2/dmol in water, which gives an
estimated a-helical content of 51% in DPC, 38% in the neutral
bicelles and 24% in water, respectively (Fig. 1).
3.2. Solution structure of transportan in zwitterionic bicelles
Two-dimensional 1H NMR spectra (TOCSY and NOESY)
were recorded for 1 mM transportan in zwitterionic bicelles at
37 C (Fig. 2) from which assignments were made. Backbone
assignments were found for all residues and around 90% of the
side-chain resonances could be assigned. Secondary chemical
shifts for the Ha and HN protons were calculated according to
Wishart and Sykes [25] (Fig. 3). Both the galanin and mas-
toparan parts of transportan display secondary Ha shifts
characteristic of a helical structure, and the HN secondary
shifts for the mastoparan part varies with a periodicity of three
to four amino acid residues, indicative of an amphipathic helix.
The structure of transportan was calculated based on 220
proton–proton distances shorter than 6 A as determined from
NOESY cross-peaks (NOEs)-derived distance constraints. The
ﬁnal solution structure of transportan is seen to adopt a helical
Fig. 2. The HN–Ha ﬁngerprint region of a TOCSY spectrum (smix ¼ 30 ms) recorded at 800 MHz for 1 mM transportan in neutral bicellar solution
([DMPC]/[DHPC]¼ 0.33) containing 50 mM phosphate buﬀer, pH 5.6, at 37 C.
Fig. 3. Structural data for transportan in neutral bicelles. (a) Ha sec-
ondary chemical shifts. (b) HN secondary chemical shifts. (c) Summary
of sequential and medium-range NOEs obtained from the NOESY
spectrum recorded with smix ¼ 100 ms.
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part of the peptide has backbone torsion angles compatible
with a helical structure as checked with PROCHECK NMR.
A hydrogen-bonding pattern characteristic of a-helical struc-
ture is seen between residues Asn15 and Ala20. There seems to
be a kink in the helix at position Ala21, since the regular
NH(i)–O(i+4) hydrogen bonding pattern is interrupted by a
NH(i)–O(i+3) hydrogen bond present in all structures within
the ensemble. The helix becomes slightly more irregular at the
C-terminal residues, since no regular hydrogen bonding pat-
tern is observed for residues Lys24 and Lys25, but is observed
for Ile26. Nevertheless, we observe a helical structure for most
of the mastoparan part of the transportan peptide. The
backbone RMSD in atomic coordinates for the helical part
(residues 15–26) is 0.15 A, which is signiﬁcantly lower than for
the whole sequence (see Table 1). The N-terminal galanin part
also seems to have a weak tendency to form a helical structure,
especially between residues Asn5 and Gly8 where the calcu-
lated / and w angles fall strictly in the helical region. The
number of medium range NOEs found in this part of the se-
quence is lower than for the C-terminus and the structure is
thus much less deﬁned (Fig. 4).
3.3. Positioning of transportan in zwitterionic bicelles
Adding the 5-doxyl- and 12-doxyl-labelled phospholipids to
the peptide-bicelle solution gave similar results in terms of
TOCSY HN–Ha cross-peak broadening. The eﬀect of the spin-
labels on the TOCSY cross-peak amplitudes in the mastoparan
part of the peptide is seen to oscillate with a periodicity of about
three amino acids (Fig. 5). The residues most aﬀected by the
two spin-labelled phospholipids within the helix are Ala20,
Ala23 and Ile26. The eﬀect is more general on the galanin part
of the peptide, but a periodicity is also seen for this part of the
peptide, especially from the 12-doxyl-labelled phospholipid,
aﬀecting residues Leu4 and Ala7 signiﬁcantly more than the
other residues. The eﬀect of both spin-labels is strongest for
Asn15, for which the cross-peak completely vanishes, similar to
what has been observed for transportan in SDS micelles [10].
Fig. 4. Structure of transportan in neutral bicelles. (a,b) Overlay of the
25 structures of transportan with lowest violation energies. The
structures were superimposed using backbone atoms in residues 3–26
(a) and residues 16–26 (b). (c) The C-terminal helix of transportan
(residues 16–27). Leu, Ile, Ala20 and Ala23 side-chain atoms are col-
ored in gray, and Lys side-chain atoms in black.
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Fig. 5. The inﬂuence of 0.5 mM 1-palmitoyl-2-steroyl-(5-DOXYL)-sn-
glycero-3-phosphocholine (solid line) and 0.5 M 1-palmitoyl-2-steroyl-
(12-DOXYL)-sn-glycero-3-phosphocholine (dashed line) on the
HN–Ha cross-peaks in a TOCSY spectrum (smix ¼ 30 ms) for trans-
portan in neutral bicelles.
Table 1
Structural statistics for the ensemble of 25 transportan structures in
q ¼ 0:33 DMPC/DHPC bicelles calculated with DYANA
Number of constraints 220
Dyana target function 0.12 0.05 A2
Maximum distance violation 0.13 0.02 A
Backbone atom RMSD (A)
All residues 2.29
Residues 3–13 0.92
Residues 15–26 0.15
Ramachandran plot regions (%)
Most favored 79.3
Allowed region 18.1
Generously allowed 1.4
Disallowed 1.2
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Previous conformational analyses of transportan, based on
CD measurements in vesicles with diﬀerent charge densities
[26], and in SDS micelles [10] show that transportan adopts ahelical structure to varying degrees (40–60%). The structure
changes only slightly with the properties of the membrane
model system, in particular the charge density of the mem-
brane surface. The present solution structure in small
q ¼ 0:33 zwitterionic bicelles suggests that the main structural
feature can be derived from the helical conformation of the
C-terminal mastoparan part of the chimeric peptide. This
clearly indicates that the structure of the mastoparan part of
the peptide is not dependent on choice of membrane model
system, or on the charge density of the membrane head-
group region. Structural investigations of both the galanin
peptide and the mastoparan peptides have been reported
previously, however, in diﬀerent membrane mimetic media
[12,27–29]. These studies show that mastoparan adopts a
helical conformation in phospholipid bicelles, and that the
galanin peptide in SDS micelles contains a series of turns, but
is overall more unstructured.
The present structure in phospholipid bicelles reveals a he-
lical conformation for the mastoparan part of transportan,
and a tendency also for the galanin part of transportan to
adopt a helical conformation. This is diﬀerent to what was
observed in the SDS study of galanin alone, and indicates a
structural diﬀerence that may be partly explained by the chi-
mera with the mastoparan peptide, and partly by the presence
of the phospholipid model system. The relatively low amount
of helical structure found in the CD results could be explained
by an equilibrium between an unstructured form in aqueous
solution and a bicelle-bound structured form. The peptide
could in principle also interact with free DHPC, since it is
known that an equilibrium exists between bicelle-bound and a
small fraction of free DHPC [13,30].
The position of transportan relative to the bicelle surface
was investigated by the addition of paramagnetic probes. The
two doxyl-labelled phospholipids have approximately the same
eﬀect on the peptide. This can be explained by a high degree of
lipid mobility in the membrane, resulting in a broad and
overlapping distribution functions for the eﬀect of the two
doxyl-labelled phospholipids [31]. The eﬀect of the probes in-
dicates the presence of an amphipathic helix in the mastoparan
part, with a hydrophobic side facing the interior of the bicelle.
There is a remarkable agreement between the spin-label results
E. Barany-Wallje et al. / FEBS Letters 567 (2004) 265–269 269and the secondary HN chemical shifts (Fig. 3(b)). Positive
secondary chemical shifts are often observed for HN protons
on the more hydrophobic sides in proteins and even more so in
the presence of a hydrophobic environment such as a mem-
brane [32–34]. Conversely, negative secondary shifts may in-
dicate interactions between the HN protons and the more
hydrophilic part of a membrane. The positive secondary shifts,
which coincide with the paramagnetic broadening eﬀect, seen
for residues Leu16, Ala20 and Ala23 thus support the for-
mation of an amphipathic helix with the hydrophobic residues
facing the interior of the bilayer. The paramagnetic probes do
not aﬀect the Lys residues in the mastoparan part signiﬁcantly
and these residues are in the structure seen to be facing one
side of the helix (Fig. 4(c)). The secondary HN chemical shifts
are similar to what has previously been found for mastoparan
in phospholipid bicelles [12,27] and for transportan in SDS
micelles [10]. Here, we are able to establish that the helix axis
of the mastoparan part in the transportan peptide resides
parallel to the membrane surface, with a hydrophobic side of
the helix facing the interior.
Turning to the galanin part of transportan, we see that resi-
dues in this part are more equally aﬀected by the spin-
labels, with a slight periodicity indicating the presence of an
amphipathic helix also for the N-terminus of transportan.
Again, the results suggest that the hydrophobic residues face the
interior of the lipid bilayer. The amphipathic character for the
galanin part is, however, not as clear-cut from the HN second-
ary chemical shifts. The structure is not as well deﬁned for this
part as for the mastoparan part of transportan, which supports
a more random distribution of the galanin residues within the
membrane bilayer. As the spin-labels are known to aﬀect both
the head-group region as well as part of the acyl chains, it is
likely that the probes will signiﬁcantly aﬀect also a disordered
peptide residing within this region of the bilayer [31].
It should be noted that several of the structural features
reported here were also seen in the previous study in SDS; the
a-helix in the mastoparan part and the peculiar hinge region
between the two helices constituted mainly by Asn15. The
major diﬀerence in the phospholipid bicelle solvent is the
partial helix in the N-terminus, and the rather clear-cut de-
termination of localization of the entire transportan peptide at
the interface between membrane and solvent.
The amphipathic helical structure found for transportan is
similar to what was previously determined for penetratin [11].
In the penetratin study, it was also found that a non-pene-
trating analog had a more perpendicular position in relation to
the membrane than penetratin itself. The ability to form an
amphipathic helical structure together with their position close
to the membrane surface could therefore be of importance in
providing a mechanism for CPP translocation. How this is
coupled to the mechanism of translocation is a question for
future work.Acknowledgements: This work was supported by the Swedish Research
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